作者: Aida Kiviniemi , Maria Gardberg , Anu Autio , Xiang-Guo Li , Vanina D. Heuser
DOI: 10.3109/0284186X.2014.925577
关键词: Positron emission tomography 、 Glioma 、 Medicine 、 In vivo 、 Pet imaging 、 Ex vivo 、 Somatostatin receptor 2 、 Pathology 、 Somatostatin analog 、 Immunohistochemistry
摘要: AbstractSomatostatin receptor subtype 2 (sstr2) is regarded as a potential target in malignant gliomas for new therapeutic approaches. Therefore, visualizing and quantifying tumor sstr2 expression vivo would be highly relevant the future development of sstr2-targeted therapies. The purpose this study was to evaluate status experimental BT4C gliomas.Methods. Rat glioma cells were injected into BDIX rat brain or subcutaneously nude mice. Tumor uptake [68Ga]DOTA-(Tyr3)-Octreotide ([68Ga]DOTATOC), somatostatin analog binding sstr2, studied by positron emission tomography/computed tomography (PET/CT). Additionally, subcutaneous tumor-bearing mice underwent PET imaging with 5-deoxy-5-[18F]fluororibose-NOC ([18F]FDR-NOC), novel glycosylated peptide tracer also targeting sstr2. Ex tissue radioactivity measurements, autoradiography immunohistochemistry performed expression.Results. Increased [68Ga]DOTATOC wa...